These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 24875272

  • 21. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study.
    Gijsen VM, van Schaik RH, Soldin OP, Soldin SJ, Nulman I, Koren G, de Wildt SN.
    Ther Drug Monit; 2014 Apr; 36(2):152-8. PubMed ID: 24089076
    [Abstract] [Full Text] [Related]

  • 22. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
    Chen YK, Han LZ, Xue F, Shen CH, Lu J, Yang TH, Zhang JJ, Xia Q.
    PLoS One; 2014 Apr; 9(10):e109464. PubMed ID: 25310192
    [Abstract] [Full Text] [Related]

  • 23. The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.
    Shilbayeh S, Zmeili R, Almardini RI.
    Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1125-36. PubMed ID: 24231473
    [Abstract] [Full Text] [Related]

  • 24. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N, Elens L, Llaudó I, Padullés A, van Gelder T, Hesselink DA, Colom H, Andreu F, Torras J, Bestard O, Cruzado JM, Gil-Vernet S, van Schaik R, Grinyó JM.
    Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
    [Abstract] [Full Text] [Related]

  • 25. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T, Monma F, Fujieda A, Nakatani K, Gayle AA, Nobori T, Katayama N, Okuda M.
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [Abstract] [Full Text] [Related]

  • 26. Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.
    Kagaya H, Niioka T, Saito M, Inoue T, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M.
    Int J Mol Sci; 2018 Mar 16; 19(3):. PubMed ID: 29547545
    [Abstract] [Full Text] [Related]

  • 27. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA, Cransberg K, Bouts AH, van Schaik RH, de Jong H, de Wildt SN, Mathôt RA.
    Clin Pharmacokinet; 2016 Sep 16; 55(9):1129-43. PubMed ID: 27138785
    [Abstract] [Full Text] [Related]

  • 28. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
    Liu S, Chen RX, Li J, Zhang Y, Wang XD, Fu Q, Chen LY, Liu XM, Huang HB, Huang M, Wang CX, Li JL.
    Acta Pharmacol Sin; 2016 Sep 16; 37(9):1251-8. PubMed ID: 27498776
    [Abstract] [Full Text] [Related]

  • 29. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.
    Everton JBF, Patrício FJB, Faria MS, Ferreira TCA, Romao EA, Silva GEB, Magalhães M.
    Eur J Clin Pharmacol; 2021 Jun 16; 77(6):879-886. PubMed ID: 33398393
    [Abstract] [Full Text] [Related]

  • 30. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A.
    Transplant Proc; 2008 Jun 16; 40(5):1690-5. PubMed ID: 18589174
    [Abstract] [Full Text] [Related]

  • 31. Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients.
    Stifft F, van Kuijk SMJ, Bekers O, Christiaans MHL.
    Nephrol Dial Transplant; 2018 Sep 01; 33(9):1668-1675. PubMed ID: 29733390
    [Abstract] [Full Text] [Related]

  • 32. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R.
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug 01; 380(2):169-77. PubMed ID: 19343327
    [Abstract] [Full Text] [Related]

  • 33. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.
    Clin Chem; 2011 Nov 01; 57(11):1574-83. PubMed ID: 21903774
    [Abstract] [Full Text] [Related]

  • 34. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, Boughattas N.
    Pharmacogenomics; 2015 Dec 01; 16(18):2045-54. PubMed ID: 26615671
    [Abstract] [Full Text] [Related]

  • 35. Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.
    Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, Mannon RB, Matas AJ, Israni AK, Jacobson PA.
    Pharmacogenomics J; 2018 May 22; 18(3):501-505. PubMed ID: 29160300
    [Abstract] [Full Text] [Related]

  • 36. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T, Fujishima N, Miura M, Niioka T, Abumiya M, Shinohara Y, Ubukawa K, Nara M, Fujishima M, Kameoka Y, Tagawa H, Hirokawa M, Takahashi N.
    Cancer Chemother Pharmacol; 2016 Jul 22; 78(1):111-8. PubMed ID: 27217047
    [Abstract] [Full Text] [Related]

  • 37. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P, Albano L, Woillard JB, Rostaing L, Kamar N, Sakarovitch C, Gatault P, Buchler M, Charpentier B, Thervet E, Cassuto E.
    Pharmacol Res; 2018 Mar 22; 129():84-94. PubMed ID: 29229354
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina.
    Maldonado AQ, Asempa T, Hudson S, Rebellato LM.
    Pharmacotherapy; 2017 Sep 22; 37(9):1081-1088. PubMed ID: 28605053
    [Abstract] [Full Text] [Related]

  • 40. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
    Cusinato DA, Lacchini R, Romao EA, Moysés-Neto M, Coelho EB.
    Br J Clin Pharmacol; 2014 Aug 22; 78(2):364-72. PubMed ID: 24528196
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.